Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: 6 - The Untold Story

‘No presumption of success’: South Carolina Democrats ready to defend early presidential primary date

WASHINGTON — A potential shakeup to the Democratic presidential nominating process could give South Carolina a rare chance to move up the party’s primary calendar and boost its standing with future White House candidates.

McClatchy Washington Bureau

Brennan: Will the USGA go morally bankrupt and allow Dustin Johnson to play the U.S. Open? Mum’s the word

The game of golf has told us forever that it is built on the pillars of honor and dignity, sportsmanship and fair play.

USA Today Sports Media Group

Graeme McDowell loses lucrative sponsorship deal after joining Saudi backed LIV event

McDowell and World number 13 Dustin Johnson have both lost their lucrative deals with the Royal Bank of Canada as golf's civil war escalates

Belfast Live

From analysis to the latest developments in health,
read the most diverse news in one place.

Graeme McDowell on 'scary' consequences of playing controversial event as he loses sponsor

The Portrush native will play in the Saudi-backed LIV Golf Invitational Series

Irish Mirror

Johnson Loses Major Sponsorship Due To LIV Golf Decision

The two-time major champion made a decision that was “too compelling to pass up.”

Sports Illustrated

McIlroy dismisses Saudi Arabia-backed opener as not a ‘proper tournament’

Rory McIlroy has taken a swipe at the first LIV event, while one sponsor has dropped two participants, Dustin Johnson and Graeme McDowell

The Guardian - UK

SI:AM | Dustin Johnson Goes Rogue

He was the biggest surprise on the list of names released for LIV Golf’s inaugural event.

Sports Illustrated

Read news from The Economist, FT, and more,
with one subscription

RBC Capital Slashes Verrica's Price Target After Third Rejection - What's Next?

Verrica Pharmaceuticals Inc (NASDAQ:VRCA) was slapped with a third FDA rejection for YCANTH (VP-102) as general contract manufacturing organization challenges continue to plague the approval. RBC Capital Markets has downgraded the stock to Sector Perform from Outperform and lowered the price target from $16 to $4. The analysts note that the issues fall outside of…

Benzinga

RBC Capital Sees Meaningful M&A Execution For This Critical Care-Focused Stock

Teleflex Inc (NYSE: TFX) hosted its Investor Day and issued plans for 2023-2025. RBC Capital Markets believe TFX is a stronger company delivering stable revenue growth in the M-HSDs, margin expansion, double-digit EPS growth, and strong FCF.

Benzinga

Ahead Of Upcoming Data On Three Programs, Analysts Remain On Sidelines For Wave Life Sciences

RBC Capital writes that Wave Life Sciences Ltd's (NASDAQ: WVE) Q1 earnings are largely incremental.

Benzinga

Why This Analyst Has 'Little Conviction' On CRISPR's Upcoming Trial Data

RBC Capital Markets says it remains on the sidelines given commercial uptake for CRISPR Therapeutics' (NASDAQ: CRSP) sickle cell disease (SCD)/beta-thalassemia (BT) capped by preconditioning and has little conviction in BCMA/CD70 data within weeks. The analysts lowered its price target to $85 from $95 to reflect higher Opex, with a Sector Perform rating. As recently…

Benzinga

RBC Capital: What To Expect When Bausch Health Companies Reports Q1 Tomorrow

RBC Capital Markets expects Bausch Health Companies Inc (NYSE: BHC) Q1 FY22 revenue of $2.02 billion (previous $2.04 billion; consensus $2.05 billion) and adjusted EBITDA of $799 million (previous $816 million; consensus $819 million).

Benzinga

RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value

RBC Capital Markets views Galapagos' NV (NASDAQ: GLPG) Q1 Jyseleca revenues in line as the story focuses on whether new leadership can unlock value from GLPG's ample balance sheet.

Benzinga

Here's Why RBC Capital Raised Price Target On Cigna

Cigna Corp (NYSE:CI) posted 1Q22 adjusted EPS well above expectations on enterprise-wide growth, with a particularly solid performance in specialty pharmacy and better than expected MCR on lower testing and treatment costs. The company raised FY22 guidance on 1Q outperformance. The analysts raised the price target to $272 from $235, with a Sector Perform rating. …

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why This Analyst Thinks Tabula Rasa's Divestiture Plans 'An Important Step'

RBC Capital Markets believe that the market has been assigning little-to-no value to Tabula Rasa HealthCare Inc's (NASDAQ: TRHC) MedWise, which has been burning cash and clouding, a strong core PACE business.

Benzinga

Analysts Expect Clarity Imminent On Intercept's NASH Story

RBC Capital Markets writes that following the Advanz deal, Intercept Pharmaceuticals Inc (NASDAQ:ICPT) should be well-capitalized into make-or-break upcoming readouts for obeticholic acid (OCA) in NASH, with REGENERATE re-analyses on deck, REVERSE reading in the next quarter. The analysts say it remains challenging to get visibility on how the efficacy/safety analyses will look,…

StockNews.com

Fresh Government Contracts Should Give Palantir Stock a Boost

Even though the momentum of Palantir Technologies (PLTR) stock has been to the downside, contrarian tech investors should seize the opportunity to grab some shares.

Benzinga

Here's Why This Analyst Cut Price Target On Regeneron

RBC Capital Markets has lowered Regeneron Pharmaceuticals Inc's price target (NASDAQ:REGN) from $679 to $647 and maintained a Sector Perform rating. Checks suggest that Dupixent (dupilumab) growth/durability should remain strong in new and existing indications, maintaining positive sentiment. The analysts also believe that the concerns about near-term Eylea competition may be overblown. However, high-dose…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why RBC Capital Sees 'Multiple High-Risk' On This Neurology-Focused Stock

RBC Capital Markets writes that Prothena Corporation plc (NASDAQ: PRTA) believes that the recent stock downside provides an entry point and that progress with the programs and improved sentiment in the space could drive appreciation.

Benzinga

Why These Analysts Cut Price Target On Teleflex

RBC Capital Markets says that Teleflex Incorporated (NYSE: TFX) delivered a Q1 beat and maintained 2022 guidance.

Benzinga

Here's How Analysts Responded To Mastercard's Q1

Analysts maintained their conviction on Mastercard Incorporated (NYSE: MA)

Benzinga

RBC Capital Remains On Sidelines For This MedTech Stock

Stryker Corporation (NYSE: SYK) reported 1Q FY22 results that beat on the top and bottom line, reflecting a solid rebound in procedure volumes in March.

Benzinga

Why This Analyst Thinks Tenet Healthcare's 'Q1 In Line On Solid Execution'

RBC Capital Markets views Tenet Healthcare Corp's (NYSE:THC) Q1 earnings in-line with expectations reflecting solid execution and labor cost management amid January omicron headwinds. The analysts have raised the price target from $89 to $104 (41% upside) with an Outperform rating. Against an increasingly difficult labor backdrop characterized by high agency utilization, Tenet could hold…

The Independent UK

Report: Chinese credit card processor rebuffs Russian banks

A Russian news outlet says China's credit card processor has refused to work with banks in Russia for fear of being targeted by sanctions over its attack on Ukraine

Benzinga

Analysts Say Acadia's Negative Pain Data Increases Focus On Pimavanserin For Alzheimer's-Related Psychosis

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) announced the primary endpoint miss of the phase 2 POC study of ACP-044 in acute postoperative pain following bunionectomy, a surgical procedure that moves toes back into the correct position. RBC Capital Markets writes that although trends of pain reduction were observed in the 400 mg QID ACP-044 arm compared…

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.